Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Mipomersen (Kynamro(®)), a second-generation 2′-O-methoxyethyl chimeric antisense oligonucleotide (ASO), inhibits the synthesis of apolipoprotein B (apoB) and is indicated in the US as an adjunct therapy for homozygous familial hypercholesterolemia (HoFH) at a dose of 200 mg subcutaneously (SC) once...

Descripción completa

Detalles Bibliográficos
Autores principales: Geary, Richard S., Baker, Brenda F., Crooke, Stanley T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305106/
https://www.ncbi.nlm.nih.gov/pubmed/25559341
http://dx.doi.org/10.1007/s40262-014-0224-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305106/
https://www.ncbi.nlm.nih.gov/pubmed/25559341
http://dx.doi.org/10.1007/s40262-014-0224-4

Ejemplares similares